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http:WHAT THIS PAPER ADDS
This is the largest meta-analysis to date to evaluate the efﬁcacy of exercise programmes in patients with
intermittent claudication. A supervised exercise therapy regimen is superior to other conservative treatment
modalities. A doseeresponse trend is found between the intensity of support and improvement in walking
capacity in this patient population.Background: A number of reviews have reported the inﬂuence of exercise therapy (ET) for the treatment of
intermittent claudication (IC). However, a complete overview of different types of ET is lacking. The aim of this
meta-analysis was to study the effect of supervision on walking capacity in patients with IC. It was hypothesized
that there was a positive treatment effect in relation to the intensity of supervision and improvement in walking
capacity (i.e., a “doseeresponse” hypothesis).
Methods: A systematic search in the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE
databases was performed. Only randomized controlled trials (RCTs) evaluating the efﬁcacy of an ET in IC were
included. Type of supervision, treadmill protocol, length of ET, total training volume, and change in walking
distance were extracted. RCTs were categorised according to type of support: no exercise, walking advice, home-
based exercise (HB-ET), and supervised exercise therapy (SET). A standardised mean difference between pre- and
post-training maximal walking distance (MWD) and pain-free walking distance (PFWD) was calculated for all
subgroups at 6 weeks, and 3 and 6 months of follow up.
Results: Thirty studies involving 1406 patients with IC were included. The overall quality was moderate-to-good,
although number of included patients varied widely (20e304). The intensity of supervision was directly related to
MWD and PFWD. SET was superior to other conservative treatment regimens with respect to improvement in
walking distances at all follow-ups. However, the difference between HB-ET and SET at 6 months of follow up was
not signiﬁcant.
Conclusion: Supervised exercise therapy for intermittent claudication is superior to all other forms of exercise
therapy. Intensity of supervision is related to improved walking distance.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd.
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In 2010, 202 million people worldwide were coping with
peripheral arterial occlusive disease (PAOD).1 During the
preceding decade, the number of affected individualsTo access continuing medical education questions on this paper,
go to www.vasculareducation.com and click on ‘CME’
rresponding author. J.A.W. Teijink, Catharina Hospital, Department of
r Surgery, P.O. Box 1350, 5602 ZA Eindhoven, The Netherlands.
il address: joep.teijink@catharinaziekenhuis.nl (J.A.W. Teijink).
-5884  2014 European Society for Vascular
. Published by Elsevier Ltd.
//dx.doi.org/10.1016/j.ejvs.2014.04.019
Open access under CC BY-NC-ND license.increased by 13.1% and 28.7% in high- and lowemiddle-
income countries, respectively.1 These huge numbers illus-
trate that PAOD has become a global health problem
affecting vast numbers of individuals. Some 50e80% of
patients with PAOD are symptomatic and suffer from
intermittent claudication (IC), the mildest manifestation of
in PAOD.2
To protect patients from cardiovascular events and
related morbidity and mortality, international guidelines
indicate that the treatment of IC should consist of cardio-
vascular risk management. Moreover, supervised exercise
therapy (SET) is advised to reduce symptoms and restore
physical function.2,3 However, widespread implementation
170 L.N.M. Gommans et al.of SET is restricted by the combination of an insufﬁcient
number of available facilities and issues of reimbursement,
awareness, and motivation.2,4e6 To overcome some of
these problems in the Netherlands, a community-based
network for SET was implemented.5 Community-based SET
solves the problem of transportation time and costs for
individual patients, as well as the restricted capacity of
hospital-based SET.7,8 Others have suggested the initiation
of exercise programmes in a home-based environment,
thereby diminishing the amount of labour-intensive super-
vision.9,10 A recent published trial revealed promising re-
sults regarding the effect of such an approach.11
Several reviews are currently available regarding the
value of different conservative treatment options in IC.12e16
However, no meta-analysis has yet compared SET with
home-based exercise, non-supervised regimens, and a
control group. A recently updated Cochrane review
compared unsupervised exercise with supervised exercise
with regard to improvement in walking.16 A second review
that was aimed at identifying components of SET contrib-
uting to maximal improvement of walking capacity only
compared supervised exercise with no exercise at all.13
Despite the use of strict inclusion criteria in both reviews,
some overlap in included trials was inevitable. Moreover,
the latter reported that intensity, duration, or programme
content were not independently associated with improve-
ment in maximal or pain-free walking distance, but the role
of support was not addressed.
The present effort aimed to evaluate the effect of various
grades of supervision on walking capacity by providing a
meta-analysis of the existing literature concerning exercise
programmes for IC. It was hypothesised that a dosee
response relationship was present between supervision and
improvement in walking capacity.METHODS
Eligibility criteria
Only randomised controlled trials (RCTs) of patients with IC
(Fontaine II/Rutherford 1e3) were eligible for inclusion in
this meta-analysis. An RCT was included if each intervention
group received at least one type of exercise, if the type of
supervision was different between study groups, if super-
vision and duration of exercise therapy (ET) exceeded 6
consecutive weeks, and if > 50% of the exercise time
included lower limb training. Outcomes had to be reported
as maximal walking distance/time (MWD/T) or pain-free
walking distance/time (PFWD/T), or both. Only English or
Dutch studies were included. Trials with a control group
undergoing invasive therapy or speciﬁc drug treatment
were excluded.Trial selection strategy
An electronic search was conducted in MEDLINE (for the
period January 1966eMarch 2013), EMBASE (January 1974
to March 2013), and the Cochrane Central Register of
Controlled Trials (CENTRAL) database (January 1966 toSeptember 2012). The search strategy contained the
following medical subject heading terms: “Arteriosclerosis”,
“Arterial Occlusive Diseases”, “Intermittent Claudication”,
“Peripheral Vascular Diseases”, “Exercise”, “Exercise Ther-
apy”, “Physical Exertion”, “Sports”, “Exercise Movement
Techniques”, “Locomotion”, “Leisure Activities”, “Fitness
Centers, Physical Exertion”. In addition, reference lists of
papers identiﬁed from these searches were hand-searched
for additional trials. Three authors (LG, RS, and HF) inde-
pendently selected trials on the basis of title and abstract. A
deﬁnite selection was based on full-text evaluation of the
report. Disagreement between the reviewers was discussed
and resolved by consensus.
Risk of bias assessment
The included articles were assessed by two authors (LG and
RS) using the Cochrane scale to determine methodological
quality and to assess the risk of bias. Blinding of staff and
patients during exercise programmes is not possible and was
therefore not taken into account. Study quality was deter-
mined using a table of risk of bias on the basis of a checklist of
design components, including random sequence generation,
allocation concealment, incomplete outcome data, and se-
lective reporting (Appendix 1). The adequacy of each cate-
gory was assessed as “low”, “unclear”, or “high” risk, as
suggested in the Cochrane Collaboration Handbook.17
Data collection and processing
Trial data were extracted by three authors (LG, HF, and RS)
using a standardised data extraction form that was checked
by a fourth author (SH). Study characteristics, year of publi-
cation, study location, and type of supervision were
collected, as well as patient group characteristics, including
mean age and sex, number of patients in each group, and
walking distances (MWD and PFWD, pre- and post-training).
The authors of individual articles were contacted for addi-
tional informationwhen therewas ambiguity ormissing data.
Where MWD/PFWD were reported, conversion into dis-
tances (metres) was performed by multiplying the time
spent on the treadmill by the given walking speed (m/s). If
standard errors (SEs) were available (and the authors did
not reply or declined the request to release unpublished
data), we converted these values into standard deviations
(SDs). In articles that reported nonparametric data, the SD
was calculated by dividing the interquartile range by 1.35,
as suggested by the Cochrane Handbook.17
Labelling of supervision
Two authors (RS and LG) independently categorised treat-
ment arms per study by classifying the type of supervision
given per arm, and the following groups were deﬁned.
1. Control group (NO-ET): Participants were mainly advised
to consolidate current levels of activities, while some
additionally received best medical treatment.
Supervised walking exercise or a walking advice was not
provided during the treatment period.
Figure 1. Flow chart of trial selection. Note. RCT ¼ randomised controlled trial.
European Journal of Vascular and Endovascular Surgery Volume 48 Issue 2 p. 169e184 August/2014 1712. Walking advice (WA): Participants were actively advised
by a physician, nurse, or physical therapist to increase
activity levels bywalking, deﬁned as a “go home andwalk”
advice. However, supervision or monitoring was absent.
3. Home-based ET (HB-ET): Participants were advised to
increase physical activity, which was monitored by
keeping a walking diary, by pedometers, or by using
physical activity monitors. They were prompted by
regular telephone calls or home visits. Active monitoring
by a physician, nurse, or physiotherapist was limited to a
maximum of twice a week.
4. SET: Participants were treated with a SET regimen with
or without an additional walking advice. The training
was hospital- or community-based under the
supervision of a physical therapist or other trained
medical personnel. The programme consisted of a least
two supervised sessions per week.
Statistical analysis
The main outcome was difference in walking distances
(MWD and PFWD) after treatment (i.e., NO-ET, WA, HB-ET,
and SET) compared with baseline measures. Results are
presented as standardised mean difference (SMD) with 95%
conﬁdence intervals (CIs), at follow-ups of 6 weeks, and 3
and 6 months. SMD expresses the size of the intervention
effect in each study relative to the variability observed inthat study. It is used as a summary statistic when studies
assess the same outcome but measure it in a variety of
ways,17 as in this meta-analysis by the use of different
treadmill protocols. A DerSimonian and Laird random-
effects model was used to pool continuous data from
each group.18 Statistical heterogeneity was examined using
the Cochran’s test and I2 statistic. Studies with an initial
supervised period followed by an unsupervised follow-up
period were analysed separately in a sensitivity analysis.
Differences in SMD between the subgroups were inves-
tigated as a means of evaluating the presence of a dosee
response relationship. Testing for subgroup differences
based on random-effects models are preferable to those
based on ﬁxed-effects owing to the high risk of false-
positive results in a ﬁxed-effect model.19 Therefore, a
random-effects model only was applied, as previously
described. A test for subgroup differences as described by
Borenstein was used.20
Review Manager software (version 5.2; Cochrane
Collaboration, Oxford, UK) was used for the calculation of
SMD, estimation of the pooled effect, testing for hetero-
geneity, and the determination of differences between
SMDs of the subgroups. A two-sided p-value < 0.05 was
considered statistically signiﬁcant. Graphs were created
with Graphpad Prism 6 (GraphPad Software, La Jolla, CA,
USA).
Table 1. Study characteristics.
First author,
year of
publication
Country Treatment Control Patients
analysed (n)
Mean age
(years)  SDf
Male
(%)
6 weeks
Follow-up
3 months
Follow-up
6 months
Follow-up
Mean PFWD (m) Mean MWD (m) Graded
treadmill
protocol
Start Follow-up Start Follow-up
Patterson, 199725 USA SET HB-ET 19 19 69.3  8.1 53 e Yes Yesa SET
HB
88
88
385
203
145
145
445
247
Yes
Treat-Jacobson, 200938 USA SET HB-ET 9 8 67.7  10.5 71 e Yes Yesa SET
HB
200
119
356
130
483
361
778
434
Yes
Gardner, 201111 USA SET HB-ET 33 29 66.0  12.0 48 e Yes e SET
HB
196
225
361b
209b
288
357
480
468
Yes
Regensteiner, 199710 USA SET HB-ET 10 10 64.5  7.0 NR e Yes e SET
HB
109
125
272
158
250
337
529
353
Yes
Savage, 200139 USA SET HB-ET 11 10 66.3  8.8 71 e Yes Yesa SET
HB
241
183
484
484
522
532
742
715
Yes
Cheetham, 200440 UK SET WA 27 28 67 (range 45e86) 73 e Yes Yes SET
WA
NR
NR
NR
NR
132
103
302
174
No
Kakkos, 200541 UK SET WA 4 9 66.5  8.0 79 Yes e Yes SET
WA
60
70
70
70
145
135
220
140
No
Gardner, 201111 USA SET WA 0 30 66.0  12 48 e Yes e SET
WA
196
200
361b
185b
288
505
480b
494b
Yes
Nicolai, 201023 NL SET WA 169 83 66.2  9.4 61 e Yes Yes SET
WA
NR
NR
NR
NR
260
260
617
400
Yes
Sanderson, 200628 Australia SET WA 13 14 63.0  9.0 57 Yes SET
WA
309
294
455c
335c
686
305
905c
310c
Yes
Hodges, 200826 UK SET WA 14 14 68.0  8.0 NR Yes Yes SET
WA
NR
NR
NR
NR
347
362
622b
405b
Yes
Stewart, 200822 UK SET WA 27 24 68  9 70 Yes Yes ˇ SET
WA
56
47
113
62
109
73
217
104
No
Parr, 200929 SA SET WA 8 8 60  13 64 Yes SET
WA
125
175
255
175c
290
460
485
430
Yes
Gardner, 201224 USA SET WA 80 27 68  8 85 Yesd Yese Yes SET
WA
176
130
365
194
383
164
663
218
Yes
Hiatt, 199042 USA SET NO-ET 10 9 60.0  12.0 100 Yes Yes e SET
NO
NR
NR
NR
NR
341
320
741b
379b
Yes
Hiatt, 199443 USA SET NO-ET 10 8 67.0  6.0 100 e Yes e SET
NO
176
203
357b
165b
512
394
784b
390b
Yes
Hobbs, 200744 UK SET NO-ET 9 9 67 (range 63e74) 78 e Yes Yesa SET
NO
60
59
127
64
99
94
206
120
No
Hobbs, 200621 UK SET NO-ET 6 7 72  NR 71 e e Yesa SET
NO
59
47
92
56
111
84
124
145
Yes
Dahllöf, 197645 Sweden SET NO-ET 10 8 61.4  1.0 79 e e Yes SET
NO
91
55
230
55
296
340
620
340
No
Gardner, 200134 USA SET NO-ET 28 24 72  1 NR e e Yes SET
NO
172
163
402
203
396
379
702
425
Yes
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Tsai, 200246 Taiwan SET NO-ET 27 20 76  4 83 e Yes e SET
NO
176
155
331b
171b
395
384
667b
405b
Yes
Langbein, 200247 USA SET NO-ET 27 25 67  9 98 e Yes Yes SET
NO
NR
NR
NR
NR
626
664
921
620
Yes
Mika, 200548 Poland SET NO-ET 41 39 61  6 83 e Yes e SET
NO
87
87
192
102
NR
NR
NR
NR
No
Mika, 200649 Poland SET NO-ET 27 28 59  8 87 Yes Yes e SET
NO
191
204
386b
210b
438
430
656b
451b
Yes
Wood, 200650 Australia SET NO-ET 7 6 60  8 69 Yes e e SET
NO
284
55
456c
55c
761
996
905c
1019c
Yes
Schlager, 201127 Austria SET NO-ET 20 19 69  10 60 e e Yes SET
NO
NR
NR
NR
NR
102
85
154
100
Yes
Mika, 201130 Poland SET NO-ET 30 31 63  7 88 Yes Yes e SET
NO
292
258
610b
258b
551
551
848b
515b
Yes
Schlager, 201251 Austria SET NO-ET 26 25 70  9 62 e Yes Yes SET
NO
NR
NR
NR
NR
102
85
132
100
No
Collins, 20119 USA HB-ET WA 64 65 66.5  10.1 69 e e Yes HB
WA
149
166
216
218
422
473
447
511
Yes
Note. PFWD ¼ pain-free walking distance; MWD ¼ maximal walking distance; SET ¼ supervised exercise therapy; HB-ET ¼ home-based exercise therapy; NR ¼ not reported; NL ¼ the
Netherlands; WA ¼ walking advice; SA ¼ South Africa; NO-ET ¼ no exercise therapy; NR ¼ not reported.
a Studies included in the sensitivity analysis.
b Follow-up data at 3 months.
c Follow-up data at 6 weeks.
d Outcome at 2 months instead of 3 months.
e Outcome at 4 months instead of 6 months.
f Unless otherwise indicated.
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Table 2. Speciﬁcation of patient population and exercise protocols.
First author Patient population Inclusion criteria Exclusion criteria Length of
programme
(wks)
Training
frequencya
Type of
exercises
Type of supervision Adherence
(%)
Patterson25 NR Age 50e75 years,
claudication > 3 months,
ABI < 0.9, no cardiac
ischaemia during exercise
test
Ischaemic leg pain,b major
comorbidities
12 3 Mixed exercise SET: 180 min/wk. In case
of missed sessions,
contact by study nurse
74
12 3 Walking HB-ET: exercise logbook.
Weekly lecture and
contact with study nurse
for 90 min
74
Treat-Jacobson38 Selection via outpatient
clinics and media
advertisement. Additional
screening by telephone
Age >18 years, ABI <0.9,
able to treadmill walk
Major comorbidities,
ischaemic leg pain, recent
MI, recent
revascularisation
procedure <3 months
12 3 Treadmill and
arm ergometry
SET: 210 min/wk 73
12 3 Walking HB-ET: walking
instructions, daily exercise
record, weekly visit to
exercise laboratory
75
Gardner11 Selection via outpatient
clinics, referral to vascular
clinics and by newpaper
advertisement
History of leg pain,
walking test limited by leg
symptoms, ABI <0.9
Asymptomatic PAOD,
exercise intolerance by
other diseases
12 3 Treadmill SET: 120 min/wk 77
12 3 Walking HB-ET: step activity
monitor and exercise
logbook. Seven visits of
15 min with exercise
physiologist to get
feedback
80
Regensteiner10 Recruitment from
vascular centre
Claudication with
restriction during daily
life, stable symptoms for 3
months, ABI <0.94
Ischaemic leg pain,b
inability to treadmill walk,
major comorbidity,
vascular surgery <6
months
12 3 Treadmill SET: up to 165 min/wk 100
12 3 Walking HB-ET: walking description
from study nurse. Weekly
call from study nurse
100
Savage39 Recruitment by three
vascular surgeons
Age >50 years, clinically
diagnosed with IC, grade I,
II, III on IC questionnaire
of the Society of Vascular
Surgery
Instable cardiopulmonary
diseases, osteoarthritis,
smoking, extreme
overweight, renal failure,
peripheral vascular bypass
12 3 Treadmill SET: up to 120 min/wk NR
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12 3 Walking HB-ET: Monthly call from
study nurse
NR
Cheetham40 Patients visiting an
outpatient vascular centre
with symptoms of
claudication
ABI <0.9, PAOD duplex
conﬁrmed, positive score
on Edinburgh
questionnaire, stable
symptoms for >6 months,
> 300 m on 6 MWT
Ischaemic leg pain,b major
comorbidity, vascular
surgery <24 months,
receiving medical agents
that were improving
symptoms for <6 months
25 2 Circuit training
in group
sessions
Training supervision for
30 min/wk. Weekly 10-
min talk on beneﬁts of
walking
97
Kakkos41 Recruitment from
vascular outpatient clinic
Stable IC symptoms >6
months, SFA occlusion
>6 cm
Previous vascular
procedure, inability to
walk on a treadmill,
ischaemic leg pain,b
polyneuropathy, exercise
intolerance caused by
other comorbidity,
walking distance <50 or
>300 m
25 3 Treadmill:
individual or
group sessions
Training supervision for
180 min/wk
50
Nicolai23 Recruitment from
vascular outpatient clinic
ABI <0.9, walking
distance <500 m
Previous SET or vascular
procedure, heart failure,
amputation or other
comorbidities impeding
SET, COPD, recent MI
52 2.5 Treadmill Training supervision for
75 min/wk and use of
accelerometers during
training
90
Sanderson28 Patients with reduced ABI
were invited by post
ABI <0.9, IC symptoms
>12 months
Unstable AP, ischaemic leg
pain, recent
cardiovascular procedures
or events, exercise
intolerance
6 3 Treadmill Training supervision NR
Hodges26 Recruitment of vascular
patients from inpatient
department
ABI <0.9, positive score
on Edinburgh
questionnaire
Inability to walk on a
treadmill, severe DM of
blood pressure control, AP
during rest, heart valve
diseases, pulmonary
problems
12 2 Treadmill Training supervision for
90 min/wk
100
Stewart22 Patients visiting an
outpatient vascular centre
with symptoms of
claudication
Symptoms of IC, ABI <0.9 Exercise intolerance
caused by comorbidity,
symptoms <3 months,
recent vascular
procedure, MI < 3
months
12 2 Circuit training Training supervision for
120 min/wk
99
Parr29 History of PAOD IC diagnosed by duplex Ischaemic leg pain,b
exercise intolerance
caused by comorbidity,
COPD
6 3 Strength
training
Training supervision for
135 min/wk
100
Continued on the next page
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Table 2-continued
First author Patient population Inclusion criteria Exclusion criteria Length of
programme
(wks)
Training
frequencya
Type of
exercises
Type of supervision Adherence
(%)
Gardner24 Recruitment from
outpatient vascular clinics
and by newspaper and
radio
History of PAOD, able to
perform walking tests, ABI
<0.9
Asymptomatic PAOD,
ischaemic leg pain, IC
symptoms reducing
medication, vascular
procedure, exercise
intolerance caused by
other comorbidities,
noncompliance
25 3 Treadmill Training supervision
for 82.5 min/wk
83
Hiatt42 NR ABI <0.95 Ischaemic leg pain,b RR
ankle <50 mmHg,
inability to walk on a
treadmill, exercise
intolerance caused by
other comorbidity
12 3 Treadmill Training supervision
for 180 min/wk
79
Hiatt43 NR IC symptoms >3 months,
restrictions in daily life,
ABI <0.9
Ischaemic leg pain,
vascular procedure <12
months, inability to walk
on a treadmill, exercise
intolerance caused by
other comorbidity
12 3 Treadmill Training supervision
for 180 min/wk
90
Hobbs44 Patients referred from
primary care to a vascular
outpatient clinic
ABI <0.9, positive score
on Edinburgh
questionnaire, maximal
walking distance of 50
e500 m
Signiﬁcant aortoiliac
disease, unable to
complete treadmill test,
MI, CVA, TIA, PTCA <3
months, congestive heart
failure, known
predisposition for
bleeding
12 2 Circuit training Training supervision
for 120 min/wk
91
Hobbs21 Patients referred from
primary care to a vascular
outpatient clinic
Maximal walking distance
of 50e500 m owing to IC
symptoms as the exercise-
limiting factor
No IC, signiﬁcant
aortoiliac disease, walking
distance <50 m
12 2 Circuit training Training supervision
for 120 min/wk
NR
Dahllöf45 Patients from outpatient
vacular clinics with IC
symptoms >1 year
IC conﬁrmed with
oscillometry, leg
symptoms after 400 m of
walking
Ischaemic leg pain,b
severe varices
26 3 Dynamic leg
exercises
Training supervision
for 90 min/wk
NR
Gardner34 Patients were originally
recruited from another
study on IC
ABI <0.97, positive score
on Rose questionnaire, >
60 years, severe
restrictions due to IC
Exercise intolerance
caused by other
comorbidities
26 3 Treadmill Training supervision
up to 120 min/wk
61
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Tsai46 NR ABI <0.95, positive score
on Rose questionnaire,
stable symptoms >3
months
Ischaemic leg pain,b
history of AP, exercise
intolerance owing to
nonvascular origin, PAOD
surgery or MI < 3 months
12 3 Treadmill Training supervision for
90 min/wk
82
Langbein47 Recruitment of patients
with history IC from
hospital records
ABI <0.95, exercise-
limiting symptoms of IC
PAOD surgery <6 months,
comorbidity that
coincides with ET
20 3 Treadmill or
outside walking
Training supervision at
least 90 min/wk
85
Mika48 Recruitment from
outpatient vascular clinics
Age 50e70 years, IC
Fountaine II, symptoms
>3 monthts, ABI <0.9
MI, PAOD surgery <12
months, relevant
comorbidity, able to walk
at a speed of 3.2 km/h,
medication
12 3 Treadmill Training supervision for
120 min/wk
84
Mika49 Recruitment from
outpatient vascular clinics
Age 50e70 years, IC
Fountaine II, symptoms
>3 monthts, ABI <0.9
MI, PAOD surgery <12
months, relevant
comorbidity, able to walk
at a speed of 3.2 km/h,
medication
12 3 Treadmill Training supervision for
120 min/wk
83
Wood50 NR IC Fountaine II Instable AP, relevant
comorbidities, vascular
procedure <12 months,
cardiac ischaemia on ECG
6 3 Treadmill Training supervision for
120 min/wk
100
Schlager27 Patients referred to
vascular clinic were
screened for recruitment
ABI <0.9, symptoms >2
weeks
Ischaemic leg pain,b
exercise intolerance
caused by other
comorbidities
26 2 Treadmill Training supervision for
110 min/wk
100
Mika30 Recruitment by records
from vascular clinic
Fontaine II, ABI <0.9, age
50e70 years, only able to
walk <150 m without
experiencing pain
History of AP or MI < 12
months, relevant
comorbidity, able to
perform a walking test
12 3 Treadmill Training supervision up to
165 min/wk
88
Schlager51 Patients referred to
vascular clinic were
screened for recruitment
ABI <0.9, symptoms >2
weeks
Ischaemic leg pain,b
exercise intolerance
caused by other
comorbidities
26 2 Treadmill Training supervision for
110 min/wk
100
Collins9 Recruitment by telephone Age >40 years, ABI <0.9,
previous vascular
procedures, DM, leg
symptoms
Amputations, critical
ischaemia, coronary
ischaemia during exercise
testing, exercise
intolerance caused by
other comorbidity
25 3 Walking HB-ET: weekly supervised
walking during group
session. Telephone
contact twice a month
83
Note. NR ¼ not reported; ABI ¼ ankle-brachial index; SET ¼ supervised exercise therapy; HB-ET ¼ home-based exercise therapy; MI ¼ myocardial infarction; PAOD ¼ peripheral arterial
occlusive disease; IC ¼ intermittent claudication; 6 MWT ¼ 6-min walking test; SFA ¼ superﬁcial femoral artery; COPD e chronic obstructive pulmonary disease; AP ¼ angina pectoris;
DM ¼ diabetes mellitus; RR ¼ Riva-Rocci; CVA ¼ cerebrovascular accident; TIA ¼ transient ischaemic attack; PTCA ¼ percutaneous transluminal coronary angioplasty;
ECG ¼ electrocardiography.
a Per week.
b Ischaemic pain at rest.
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178 L.N.M. Gommans et al.RESULTS
Study selection
In the MEDLINE and EMBASE search, 2544 studies were
identiﬁed. Another 240 potentially relevant studies were
found by a search using the CENTRAL library, and a hand
search yielded another eight eligible studies. After removing
duplicates and selection based on title and abstract, 108
studies underwent a full-text review. Seventy-eight studies
were excluded by failing to meet predeﬁned criteria. In
total, 28 RCTs met all the inclusion criteria. A ﬂow chart of
the trial selection is given in Fig. 1.Study characteristics
A total of 1406 participants (68% men; mean age 68 years)
was studied (Table 1). All trials were conducted between
1974 and 2012 in eight different countries. The NO-ET group
was formed on the basis of data derived from 16 trials con-
taining a total of 262 participants (Table 1). The WA group
was formed on the basis of 10 trials with a total of 302
participants (Table 1). Generally, walking instructions were
provided at baseline. Patients were mostly advised to
continue to walk to near maximal pain. One study provided
patients with an additional brochure,21 while in another
patients were educated using video material.10 Two studies
stipulated that patients did not receive any lifestyle coaching
or risk factor management.11,22 The HB-ET group consisted of
140 patients obtained from six trials (Table 1). Patients
received similar walking advice to the WA group, although
their regimens were supplemented with weekly telephoneFigure 2. Maximal (MWD) and pain-free walking distances (PFWD)
for the different support types at the 6-week follow-up. Note. Error
bars correspond to 95% conﬁdence interval of the calculated
standardised mean difference (SMD). NO-ET ¼ no exercise ther-
apy; WA ¼ walking advice; HB-ET ¼ home-based exercise therapy;
SET ¼ supervised exercise training; n ¼ number of participants for,
respectively, MWD and PFWD, separated by forward slash. *Sig-
niﬁcant difference (p < .05) compared with NO-ET. xSigniﬁcant
difference (p < .05) compared with WA. #Signiﬁcant difference
(p < .10) compared with NO-ET. þSigniﬁcant difference (p < .05)
compared with baseline value.contact.9e11,23e25 In two studies, participants had to log
their exercise,9,11 while in a third study participants received
SET once a week.10
All trials used a SET regimen as comparator (n ¼ 702),
except for one study that compared a home-based exer-
cise regimen with a group receiving a walking advice.10 In
seven trials, patients were treated twice a week with
SET,21,26e31 while in the remaining trials SET was given
three times a week (Table 2). The length of the ET pro-
grammes varied between 6 and 52 weeks with nine, 20,
and 16 trials lasting 6 weeks, and 3 and 6 months,
respectively (Table 2). One trial consisted of a WA group,
an HB-ET group and a SET group; all three arms were
included.11 A graded treadmill protocol was used in 23
trials, while the remaining seven used a ﬁxed protocol
(Table 1). Outcome was based on a conversion from a
time-to-distance format in eight studies.Risk of bias assessment
The risk of bias is given in Appendix 2. Of the included
trials, 83% reported random sequence generation,
whereas a mere 27% used allocation concealment. The
outcome assessor was blinded for intervention in 23% of
the trials. In 57% of the trials, correct handling of
incomplete outcome measures was reported, while a
description of all outcome measures was provided in 93%
of the trials. The overall quality of included trials was
rated as moderate-to-good.Figure 3. Maximal (MWD) and pain-free walking distances (PFWD)
for the different support types at the 3-month follow-up. Note.
Error bars correspond to the 95% conﬁdence interval of the
calculated standardised mean difference (SMD). NO-ET ¼ no ex-
ercise; WA ¼ walking advice; HB-ET ¼ home-based exercise
training; SET ¼ supervised exercise training; n ¼ number of par-
ticipants for, respectively, MWD and PFWD, separated by forward
slash. *Signiﬁcant difference (p < .05) compared with NO-ET.
xSigniﬁcant difference (p < .05) compared with WA.
ˇ
Signiﬁcant
difference (p < .05) compared with HB-ET. þSigniﬁcant difference
(p < .05) compared with baseline value.
Figure 4. Maximal (MWD) and pain-free walking distances (PFWD)
for the different support types at the 6-month follow-up. Note.
Error bars correspond to the 95% conﬁdence interval of the
calculated standardised mean difference (SMD). NO-ET ¼ no ex-
ercise; WA ¼ walking advice; HB-ET ¼ home-based exercise
training; SET ¼ supervised exercise training; n ¼ number of par-
ticipants for, respectively, MWD and PFWD, separated by forward
slash. *Signiﬁcant difference (p < .05) compared with NO-ET.
xSigniﬁcant difference (p < .05) compared with WA.
ˇ
Signiﬁcant
difference (p < .05) compared with HB-ET. #Signiﬁcant difference
(p < .10) compared with NO-ET. þSigniﬁcant difference (p < .05)
compared with baseline value.
Figure 5. Maximal (MWD) and pain-free walking distances (PFWD)
for the different support types at the 6-month follow-up: Sensi-
tivity analysis. Note. Error bars correspond to the 95% conﬁdence
interval of the calculated standardised mean difference (SMD).
NO-ET ¼ no exercise; WA ¼ walking advice; HB-ET ¼ home-based
exercise training; SET ¼ supervised exercise training; n ¼ number
of participants for, respectively, MWD and PFWD, separated by
forward slash. *Signiﬁcant difference (p < .05) compared with NO-
ET. xSigniﬁcant difference (p < .05) compared with WA.
ˇ
Signiﬁcant
difference (p < .05) compared with HB-ET. #Signiﬁcant difference
(p < .10) compared with NO-ET. þSigniﬁcant difference (p < .05)
compared with baseline value.
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Six weeks. Sixteen studies reported data on MWD and 13
on PFWD at 6 weeks of follow up. No studies that investi-
gated the effect of home-based exercise on walking dis-
tances at 6 weeks of follow up were found. A non-
signiﬁcant effect on MWD was present for both the NO-
ET and WA programmes, while with regard to PFWD both
programme groups showed a signiﬁcant increase in SMD.
The SET regimen demonstrated a signiﬁcant increase in
SMD of 0.90 (95% CI 0.67e1.13) and 0.94 (95% CI 0.64e
1.24) for MWD and PFWD, respectively (Fig. 2). Signiﬁcant
differences between groups were only found when
comparing with the SET group (Fig. 2). Heterogeneity was
absent for all groups on MWD and PFWD (all I2 < 15%;
p > .32).
Three months. The results of MWD were reported in eight,
six, ﬁve, and 20 trials for the NO-ET, WA, HB-ET, and SET
groups, respectively. PFWD was described in six, three, ﬁve,
and 13 trials for the subsequent groups. A signiﬁcant in-
crease in MWD was found for the WA, HB-ET, and SET
programmes, whereas only the SET programme revealed a
signiﬁcant effect for PFWD, too (Fig. 3). The SET programme
showed a signiﬁcant difference compared with all other
groups. MWD was also signiﬁcantly higher in the HB-ET
group compared with the NO-ET one. There was no het-
erogeneity for all groups on MWD and PFWD (all I2 < 18%;
p > .29), except for the SET group (MWD I2 ¼ 83%;
p < .001, PFWD I2 ¼ 87%; p < .001).Six months. The results of MWD were reported in six, ﬁve,
one, and nine trials for NO-ET, WA, HB-ET, and SET groups,
respectively. PFWD was described in two, three, one, and
four trials, respectively. A non-signiﬁcant increase in
MWD and PFWD compared with baseline measurements
was found for the NO-ET group. However, for the WA and
SET groups, the increase in MWD and PFWD was signiﬁ-
cant. Between-groups analysis showed signiﬁcant differ-
ences in MWD and PFWD in the SET and WA groups
(Fig. 4).
The follow-up period was longer than the actual exercise
programme in six trials.9,23,24,27e29 The results of these
trials were added to the 6-month results and used in the
sensitivity analysis (Fig. 5). In this analysis, MWD was
described in eight, six, four, and 15 trials for the NO-ET, WA,
HB-ET, and SET groups, while PFWD was found in four, four,
four, and 10 trials, respectively (Fig. 5). SET results were
superior with an SMD of 0.96 (95% CI 0.76e1.16) and 0.89
(95% CI 0.65e1.14) for MWD and PFWD, respectively.
Regarding both outcomes, the SET results were also signif-
icantly better compared with the NO-ET and WA groups.
Homogeneity was observed for all groups on both out-
comes (all 0% < I2 < 62%; p > .07).DISCUSSION
The aim of this meta-analysis was to study the effect of
supervision on the improvement of walking distance in
180 L.N.M. Gommans et al.patients with IC. The ﬁndings demonstrate a superior role
of SET, as signiﬁcant effect sizes >0.8 for all the follow up
periods were found. These effects are generally considered
as “large”.32 Moreover, the results of SET were signiﬁcantly
better compared with the three other types of ET. Although
we failed to demonstrate signiﬁcant differences between all
groups mutually, a doseeresponse trend was present with
increasing supervision resulting in larger walking distances,
most evident for PFWD, at 6 months of follow up. The
results indicate that exercise programmes supplemented
with supervision have signiﬁcant beneﬁcial effects on
walking capacity, which is in line with the existing data.13,16
One may question the additional value of yet another
meta-analysis, as various other reviews have been pub-
lished previously.12e16 For instance, Fakhry et al.13
described the effectiveness of SET on walking distances,
although they failed to include the factor supervision in the
overview. By extending the number of included trials
included herein, there was conﬁdence that the results were
genuine. By doing so, the total number of participants was
increased by 50%. Moreover, the present study is the ﬁrst to
include three conservative treatment arms, including a
control group, facilitating a more extensive comparison.
Second, it was judged that evaluation of the factor support
was required. Third, the alternative method of calculation
used in this review allowed for evaluation of the four in-
dividual groups, as well as a comparison of them. As
calculation of SMDs was based on group pre- and post-
training values, signiﬁcant differences reﬂect the actual ef-
fect of any treatment. In addition, signiﬁcant differences in
SMDs between groups represent the difference in effect
between groups.
Intuitively, one would think that a doseeresponse
relationship would be present between the intensity of
support and increased walking performance, as a com-
parison between SET and non-supervised regimens has
already demonstrated the additional value of supervi-
sion.16 Whether this is obvious or not, a doseeresponse
relationship was never identiﬁed. A clear doseeresponse
trend was demonstrated in this review, but as not all dif-
ferences between groups were statistically signiﬁcant, a
genuine relationship was not revealed. Conversely, failing
to identify such a relationship does not necessarily mean
that there is none. Moreover, comparing the levels of
statistical signiﬁcance of the results is misleading given the
low power and variation in number of participants per
subgroup. However, this review included the largest
number of participants so far;17 and as such, this ﬁnding
may have profound consequences on the structure of
these and future programmes.
Despite the overwhelming evidence supporting the use
of supervised exercise programmes for IC,12,13,16 and the
class I recommendation by three leading sets of interna-
tional guidelines,2,3,33 uncertainty surrounds the relative
contribution of all components of an optimal SET pro-
gramme.13 Moreover, the optimal length of a SET pro-
gramme is a matter of debate. Gardner et al.34 described a
tendency of mid-length programmes (12e26 weeks)leading to greater improvement in MWD and PFWD than
shorter (<12 weeks) or longer term (>26 weeks) pro-
grammes. Gardner et al.34 also concluded that walking
distances increased rapidly within the ﬁrst 2 months of
exercise rehabilitation. With respect to the support
component, this meta-analysis conﬁrms these ﬁndings, as
the effect after 3 months of SET (SMD 1.28; 95% CI 0.94e
1.62) was larger than the effect after 6 months of training
(SMD 0.96; 95% CI 0.76e1.16). Moreover, the SET results
after 6 months of follow up were not signiﬁcantly
different from the HB-ET group, suggesting that extra
supervision does not result in better outcomes after a
long period of training and demonstrating the potential
value of HB-ET.
Consequently, a 3-month SET programme appears to be
the most preferable, but given the limited utilisation of
SET in daily practice35,36 and lessons learned in the
available cardiac rehabilitation programmes worldwide,
ongoing programme modiﬁcations could possibly lead to a
more viable supervised exercise schedule for patients with
IC. After 3 months of training, SET may be replaced by a
home-based programme, as this extensive meta-analysis
demonstrated an equivalent effect of SET and HB-ET af-
ter 6 months. HB-ET may be more cost-effective by
limiting expensive supervision and reducing issues with
regard to training facilities. Interestingly, monitoring op-
tions for HB-ET could be extended by incorporating
eHealth and mHealth technologies.4,35 Such technologies
may increase adherence and consequent effectiveness.
Therefore, future research should focus on the cost-
effectiveness of home-based programmes to elucidate
the optimal mixture of home-based and supervised
training.
Some limitations of this meta-analysis should be
addressed. First, the methodological quality of original
RCTs is not always optimal, in particular questionable
allocation concealment and lack of blind outcome
assessment. As a consequence, the effect of SET may have
been overestimated in individual studies. However,
knowledge about the appropriateness of patients for SET
is not yet available, making favourable allocation unlikely.
Moreover, the use of standardised exercise testing pro-
cedures and quantitative outcome measures may
compensate for the lack of blind outcome assessment.
Second, the sample size of some studies was limited (<10
participants per treatment arm), which may have resulted
in imprecise effect estimates. Third, the calculation of
SMDs in order to be able to compare more than two
groups was chosen. Therefore, interpretation of the
overall intervention effect can be difﬁcult as it is reported
in units of SD rather than in metres. On the one hand,
however, in reality, the intervention effect is a difference
in means and not a mean of differences.17 On the other
hand, conversion to SMDs allowed the comparison of
walking distances, which were assessed with different
treadmill tests. Fourth, large diversity was observed in the
HB-ET group with regard to the supervision strategy (e.g.,
diary, pedometers, or physical activity monitors),
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of this group was also considerably smaller than the other
three groups. These effects may potentially have contrib-
uted to an inaccurate effect assessment and may also
explain the absence of a signiﬁcant difference between
the WA and HB-ET groups. Fifth, outcomes were
measured using a treadmill test. Patients in the SET group
may have been favoured as they were accustomed to
training on a treadmill, leading to a potential over-
estimation of the results of SET. Finally, the results of the
present meta-analysis may also be explained, in part, by a
difference in the extent of support or a difference in
training regimen (e.g., outdoor walking in the WA group
compared with mainly indoor walking in the SET group).
However, this potential bias is inherent to the retrospec-
tive methodology, as groups were not identical in terms of
training programme. An interesting contribution to this
discussion is provided by a recent study that found no
difference in walking performance when comparing two
different training regimens.37 Therefore, the exact effectAPPENDIX 1. METHODOLOGICAL QUALITY OF TRIALS INCLUDEof training type on walking distance has not yet been
identiﬁed.CONCLUSION
SET is superior to other forms of ET in patients with IC.
Increased supervision tends to lead to a larger improve-
ment in walking distance. However, at the 6-month follow-
up, the efﬁcacy of home-based programmes may be equal
to SET. Future research should focus on identifying an
optimal mixture of supervised and home-based
programmes.CONFLICT OF INTEREST
None.FUNDING
None.D IN THE META-ANALYSIS.
APPENDIX 2. OVERVIEW OF EXCLUDED STUDIES AFTER FULL-TEXT REVIEW.
Author and year Journal Reasons for exclusion
Degischer, 2002 Vasc Med. 2002;7(2):109-15 No RCT
Nielsen, 1977 Ugeskr Laeger. 1977;139(46):2733-6 Language
Arosio, 2001 Life Sci. 2001;69(4):421-33 Research with drug treatment
Collins, 2003 Med Sci Sports Exerc. 2003;35(3):384-93 Less than 50% walking
Gardner, 2002 J Cardiopulm Rehabil. 2002;22(3):192-8 Data already use in other publication
Gibellini, 2000 Int Angiol. 2000;19(1):8-13 Less than 6 weeks of training
Lepantalo, 1991 Clin Rehabil. 1991;5:65-9 No difference in supervision between groups
McDermott, 2004 J Cardiopulm Rehabil. 2004;24(3):187-96 Different patient population
Nawaz, 2001 J Vasc Surg. 2001;33(2):392-9 Only cycling
Taft, 2001 Eur J Vasc Endovasc Surg. 2001;22(2):114-23 No outcome measures on walking
Taft, 2004 Eur J Vasc Endovasc Surg. 2004;27(1):24-32 No outcome measures on walking
Tisi, 1997 Eur J Vasc Endovasc Surg. 1997;14(5):344-50 Less than 6 weeks training
Bronas, 2011 J Vasc Surg. 2011;53(6):1557-64 Data already use in other publication
Ciuffeti, 1994 Int Angiol. 1994 Mar;13(1):33-9 Research with drug treatment
Collins, 2005 J Cardiovasc Nurs. 2005;20(3):177-85 Data already use in other publication
Fahkry, 2011 Arch Phys Med Rehabil. 2011;92:1066-73 Data already use in other publication
Fowler, 2002 Aust J Physiother 2002;48(4):269-75 No outcome measures on walking
Gardner, 2005 J Vasc Surg. 2005;42(4):702-9 No difference in supervision between groups
Greenhalgh, 2008 Eur J Vasc Endovasc Surg. 2008;36(6):680-8 No difference in supervision between groups
Grizzo, 2011 Vasa. 2011;40(5):390-7 No difference in supervision between groups
Krause, 1974 Munch Med Wochenschr. 1974;116(8):385-8. Different research scope
Kruidenier, 2011 J Vasc Interv Radiol. 2011;22(7):961-8 Patients underwent invasive therapy
Leon, 2005 Clin J Sport Med. 2005;15:285-6 No outcome measures on walking
Manfredini, 2008 Circ J. 2008;72(6):946-52 No difference in supervision between groups
Meneses, 2011 J. Vasc. Nurs. 2011;29, 81-86 Different research scope
Murphy, 2012 Circ. 2012;125(1):130-9 Research with invasive therapy
Pinto, 1997 J Aging Phys Act. 1997;5:311 Data already use in other publication
Ritti-Dias, 2010 J Vasc Surg. 2010;51(1):89-95 No difference in supervision between groups
Spronk, 2009 Radiol. 2009;250(2):586-95 Research with invasive therapy
Steiner, 2009 Eur Heart J. 2009;30(984):985 Data already use in other publication
Tebbutt, 2011 Phys Ther. 2011;97:244-249 Less than 50% walking
Tew, 2009 Clin Sci. 2009;117(12):405-13 Less than 50% walking
Van Asselt, 2011 Eur J Vasc Endovasc Surg. 2011; 41, 97-103 No outcome measures on walking
Walker, 2000 J Vasc Surg. 2000;31(4):662-9 Less than 50% walking
Wood, 2006 Clin Sci. 2006;111(6):401-9 No outcome measures on walking
Zwierska, 2005 J Vasc Surg. 2005;42(6):1122-30 Less than 50% walking
Mazari, 2012 Br J Surg. 2012;99(1):39-48 Research with invasive therapy
Mohler 2011 Vasc Med. 2011;16(5):346-53 No exercise intervention
Cousin 2011 Ann Phys Rehabil Med. 2011;54(7):429-42 No RCT
Duscha, 2011 Arterioscler Thromb Vasc Biol. 2011;31(11):2742-8 No outcome measures on walking
Szymanska 2011 Ortop Traumatol Rehabil. 2011;13(3):279-92 No difference in supervision between groups
Malagoni 2011 Circ J. 2011;75(9):2128-34 No outcome measures on walking
Villemur, 2011 Ann Phys Rehabil Med. 2011;54(5):275-81 Language
Nordanstig, 2011 Eur J Vasc Endovasc Surg. 2011;42(2):220-7 Research with invasive therapy
Vitale, 2011 Pharmacol Res. 2011;63(4):278-83 Different research scope
Franz, 2010 Vascular. 2010;18(6):325-35 No RCT
Hiatt, 2011 J Cardiopulm Rehabil Prev. 2011;31(2):125-32 Research with drug treament
Allen, 2010 Free Radic Biol Med. 2010;49(6):1138-44 Different research scope
Casto-Sanchez, 2010 Med Clin (Barc). 2010;134(3):107-10 Language
Martinez, 2009 J Vasc Nurs. 2009;27(1):2-7 Different research scope
Andreozzi 2008 Int Angiol. 2008;27(5):401-7 No RCT
Spronk, 2008 J Vasc Surg. 2008;48(6):1472-80 Data already use in other publication
Carlon, 2008 Monaldi Arch Chest Dis. 2008;70(2):76-83 Language
Gardner, 2008 J Cardiopulm Rehabil Prev. 2008;28(4):258-65 Research with drug treament
Saxton, 2008 Eur J Vasc Endovasc Surg. 2008;35(5):607-13 No outcome measures on walking
Wang 2007 Clin Rehabil. 2007;21(7):579-86 Research with drug treament
Nylaende, 2007 Vasc Med. 2007;12(4):275-83 Research with invasive therapy
Bendermacher, 2007 J Vasc Surg. 2007;45(6):1192-6 No RCT
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Author and year Journal Reasons for exclusion
Andreozzi, 2007 Int Angiol. 2007;26(1):12-7 No outcome measures on walking
Slørdahl, 2005 Scand Cardiovasc J. 2005;39(4):244-9 No difference in supervision between groups
McGuigan, 2001 J Gerontol A Biol Sci Med Sci. 2001;56(7):B302-10 No difference in supervision between groups
Cachovan, 2001 Angiology. 2001;52(6):381-91 Research with drug treament
Belcaro, 2000 Angiology. 2000;51(8 Pt 2):S15-26 Research with drug treament
Ubels, 1999 Diabetes Care. 1999;22(2):198-201 Different patient population
Perkins, 1996 Eur J Vasc Endovasc Surg. 1996;11(4):409-13 Different patient population
Regensteiner, 1996 J Vasc Surg. 1996;23(1):104-15 Data already use in other publication
Hiatt, 1996 J Appl Physiol. 1996;81(2):780-8 No outcome measures on walking
Streminski, 1992 Vasa. 1992;21(4):392-402 Language
Schefﬂer, 1991 Vasa Suppl. 1991;33:350-2 Language
Lundgren, 1989 Clin Sci (Lond). 1989;77(5):485-93 No outcome measures on walking
Mannario, 1989 Angiology. 1989;40(1):5-10 No outcome measures on walking
Diehm, 1989 Vasa Suppl. 1989;28:26-30 No data on effect of exercise intervention
Kiesewetter, 1987 Dtsch Med Wochenschr. 1987;112(22):873-8 Language
Lepantalo, 1984 Scand J Rehabil Med. 1984;16(4):159-62 Data already use in other publication
White, 1984 JAMA. 1983 Jun 24;249(24):3355-6 No actual research data
Sandri, 2005 Circ. 2005;111:3391-9 Less than 6 weeks training
Gelin, 2001 Eur J Vasc Endovasc Surg. 2001;22(2):107-13 Different follow up time
Crowther, 2008 Vasc Surg. 2008;47(2):303-9 Different follow up time
Note. RCT ¼ randomised controlled trial.
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